To correlate the clinical implications in NSCLC with the mechanism identified in vitro, the effects of afatinib on the CIP2A-PP2A-AKT pathway in these tumor were examined by Western blot and PP2A activity assay. This evidence concerns the gene CIP2A and neoplasm.